Tranexamic acid, also known as hemostatic cyclic acid, is an anti-fibrinolytic drug with the following clinical effects: I. Post-traumatic or post-surgical bleeding in the prostate, urethra, lung, brain, uterus, adrenal gland, thyroid, liver and other organs rich in fibrinogen activator. Second, abortion, early placental abruption, stillbirth and fibrinolytic bleeding caused by amniotic fluid embolism. To prevent or alleviate bleeding in patients with hemophilia due to coagulation factor VIII (VIII) or coagulation factor IX (IX) deficiency, after tooth extraction or oral surgery. IV. Treatment of hereditary angioedema may reduce the number and severity of attacks. V. Active bleeding occurring in patients with hemophilia. VI. It is also effective in the treatment of chloasma. Seven, the treatment of acute promyelocytic leukemia requires antifibrinolytic treatment with tranexamic acid when the patient shows hyperfibrinolytic manifestations.